5-Amino-1MQ vs Cagrilintide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: 5-amino-1-methylquinolinium, NNMT Inhibitor
First, a correction worth making loudly: 5-amino-1MQ is not a peptide. It is a small molecule (5-amino-1-methylquinolinium), and it gets lumped in with research peptides mostly because of the crowd that sells it. It blocks an enzyme called NNMT, and in obese mice it produced weight and fat loss without the animals eating less. No human trials have been published.
Also: AM833, NN9838
Cagrilintide (also called AM833) is a long-acting synthetic analog of amylin, the gut-brain satiety hormone co-secreted with insulin by pancreatic beta cells. It is an investigational once-weekly injectable being developed by Novo Nordisk for obesity, most prominently as the amylin half of CagriSema (cagrilintide plus semaglutide). It is not yet approved as a standalone drug, but it has cleared phase 2 trials and is in late-stage development.
Key Comparison Insights
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Cagrilintide has stronger research evidence (Human Trials) compared to 5-Amino-1MQ (Animal Studies).
Detailed Comparison
| Attribute | 5-Amino-1MQ | Cagrilintide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | NNMT (nicotinamide N-methyltransferase) takes nicotinamide and tags it with a methyl group borrowed from SAM, the cell's main methyl donor, producing 1-methylnicotinamide. In fat tissue, high NNMT activity is thought to drain both NAD+ precursors and SAM, nudging cells toward storing fat. The hypothesis behind 5-amino-1MQ is straightforward: inhibit NNMT, and you preserve NAD+ and SAM inside adipocytes, which shifts them away from fat storage and toward burning energy. The published mouse work showed NNMT inhibition raising intracellular NAD+ and SAM, consistent with that idea. It is a plausible, well-reasoned mechanism, but in humans it remains a hypothesis, not a demonstrated effect. | Cagrilintide is a non-selective agonist of the amylin and calcitonin receptor family. It activates amylin receptors (which are calcitonin receptors paired with RAMP accessory proteins) to signal satiety in the brain, slow gastric emptying, and blunt the post-meal glucagon rise. Mechanistic work in mice shows it reduces body weight mainly through amylin receptors AMY1R and AMY3R acting in the hindbrain, with the area postrema as a key entry point and downstream signaling through the nucleus of the solitary tract and parabrachial nucleus. Notably, weight loss in those studies persisted even after the acute appetite-suppressing effect faded, hinting at effects on energy balance beyond simple food-intake reduction. Chemically it is built on a pramlintide-like 37-amino-acid backbone with substitutions and a fatty-diacid chain attached to extend its half-life to roughly a week, enabling once-weekly dosing. |
| Common Dosing | 50-75 mg daily Once daily, morning | 2.4 mg weekly Once weekly |
| Administration | Subcutaneous injection or oral | Subcutaneous injection once weekly |
| Typical Duration | 4-6 weeks (cycling recommended) | Long-term / chronic use expected |
| Best Time to Take | Morning, fasted | Any consistent time weekly |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The headline study (Neelakantan et al.) tested small-molecule NNMT inhibitors in diet-induced obese mice. Treated animals lost weight (roughly 5% from baseline over about 11 days in that work) and shed white adipose mass, with reduced circulating cholesterol and no change in food intake, which points to a metabolic effect rather than appetite suppression. That is genuinely interesting preclinical data. But here is the honest part: the entire evidence base is animal and cell studies. There are no published human clinical trials demonstrating that 5-amino-1MQ causes fat loss, raises energy expenditure, or is safe over time in people. Claims of specific human fat-loss percentages from vendors are not backed by trial data. Treat it as an early-stage research compound, not a proven product. | Cagrilintide has real human data, which sets it apart from most peptides in this category. In a 2021 Lancet phase 2 dose-finding trial (Lau et al.), once-weekly cagrilintide at 4.5 mg produced about 10.8% mean body weight loss over 26 weeks, beating both placebo (around 3%) and liraglutide 3.0 mg (around 9%), establishing that amylin agonism alone can drive clinically meaningful weight loss. Its bigger story is combination therapy: paired with semaglutide as CagriSema, it advanced into phase 3 REDEFINE trials for obesity and type 2 diabetes, with reported weight loss in the low 20% range, though final results came in somewhat below the most optimistic expectations. Side effects are dominated by the expected gastrointestinal effects (nausea, vomiting) common to gut-hormone drugs. As of 2026 cagrilintide is investigational and not FDA-approved on its own. The evidence is genuinely human and well-controlled here, which is rare, but it is still a drug under regulatory review rather than an approved therapy. |
Frequently Asked Questions: 5-Amino-1MQ vs Cagrilintide
What is the difference between 5-Amino-1MQ and Cagrilintide?
5-Amino-1MQ is a weight loss peptide that first, a correction worth making loudly: 5-amino-1mq is not a peptide. it is a small molecule (5-amino-1-methylquinolinium), and it gets lumped in with research peptides mostly because of the crowd that sells it. it blocks an enzyme called nnmt, and in obese mice it produced weight and fat loss without the animals eating less. no human trials have been published. Cagrilintide is a weight loss peptide that cagrilintide (also called am833) is a long-acting synthetic analog of amylin, the gut-brain satiety hormone co-secreted with insulin by pancreatic beta cells. it is an investigational once-weekly injectable being developed by novo nordisk for obesity, most prominently as the amylin half of cagrisema (cagrilintide plus semaglutide). it is not yet approved as a standalone drug, but it has cleared phase 2 trials and is in late-stage development. The main differences lie in their mechanisms of action and clinical applications.
Which is better, 5-Amino-1MQ or Cagrilintide?
Neither is universally "better" - the choice depends on your specific goals. 5-Amino-1MQ is typically used for weight loss purposes, while Cagrilintide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can 5-Amino-1MQ and Cagrilintide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using 5-Amino-1MQ and Cagrilintide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.